Thyroid Cancer Trial, Recruiting NCT04693377 Sponsor: M.D. Anderson Cancer Center Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT04693377
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with cancer that has spread to the bones (bone metastases), confirmed by a scan.
  • Your cancer is one of the following types: kidney cancer (renal cell carcinoma), bladder/urinary tract cancer (urothelial carcinoma), prostate cancer that no longer responds to hormone therapy, sarcoma, thyroid cancer, colorectal cancer, or melanoma.
  • You have one specific bone lesion that doctors have confirmed can be treated with both freezing therapy (cryoablation) and focused radiation (SBRT).
  • The bone lesion being treated is 7 cm (about 2.75 inches) or smaller.
  • The pain from that lesion is at least 4 out of 10 on a standard pain scale.
  • The painful area matches a visible tumor on a CT scan, MRI, or ultrasound.
  • Your doctors estimate you have at least 3 months to live.
  • Your blood platelet count is above a certain level (confirm with trial site), tested within 6 weeks of screening.
  • Your blood clotting measure (INR) is within an acceptable range, tested within 6 weeks of screening.
  • If you take blood thinners or anti-inflammatory medications (such as aspirin, ibuprofen, or heparin), you are able to stop taking them at least 48 hours before the procedure, or as agreed with the doctor.
  • You are generally able to carry out normal daily activities with little or no difficulty (confirm with trial site what this means for your situation).
  • If you are a woman who could become pregnant, you have either tested negative for pregnancy or are confirmed to be past menopause.
  • You have received prior cancer treatments (such as chemotherapy, immunotherapy, or targeted therapy) — all are acceptable.
  • You are willing and able to read and sign a consent form agreeing to take part.

Who may not be able to join:

  • You have already had treatment directly to the target lesion, such as any type of ablation, embolization, radiation, or surgery.
  • You are currently taking part in another clinical trial involving an experimental treatment.
  • You have serious uncontrolled health conditions, such as an active infection, certain lung diseases, unstable heart problems, or mental health/personal circumstances that would make it hard to follow the study requirements.
  • You are pregnant or breastfeeding, or you could become pregnant and are not using effective contraception.
  • The bone lesion being targeted is located in the spine or the skull.
  • Your white blood cell count (a specific type called neutrophils) is below a certain level within 6 weeks of screening (confirm with trial site).
  • You have an active infection at the time of screening.
  • The target lesion has caused a broken bone (fracture) that cannot be stabilized with a minimally invasive procedure.
  • The lesion is in a major weight-bearing bone in the lower body (such as the thigh or shin) and has destroyed more than half of the outer bone layer, or the lesion is in the hands or feet.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rahul A Sheth, MD, M.D. Anderson Cancer Center

Phone: 713-745-0652

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
16 March 2021
Est. completion
1 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pain response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov